Today, SAB Biotherapeutics announced that its polyclonal antibody therapy SAB-176 for the treatment of seasonal influenza has reached its primary endpoint in a Phase 2a clinical trial for the treatment of seasonal influenza
Among adults who were challenged by the virus, SAB-176 significantly reduced the viral load and clinical symptoms compared with placebo
It is worth mentioning that the company's technology platform uses genetically engineered cattle to produce fully humanized polyclonal antibodies
This result is also a clinical proof of concept for this technology platform
Influenza virus infection is one of the most common infectious diseases, causing 2.
5 to 5 million hospitalizations worldwide every year
Due to the rapid mutation of the influenza virus, the current influenza vaccine does not provide high protection effectiveness, and there are not many approved drugs for the treatment of influenza
SAB-176 is a fully humanized broad-spectrum neutralizing polyclonal antibody
Unlike monoclonal antibodies, polyclonal antibodies contain a variety of different antibody types, which target a variety of different antigens associated with influenza viruses
Pre-clinical studies have shown that it can have a wide range of protective effects on different influenza virus strains
SAB Biotherapeutics' technology platform uses genetically engineered cattle to produce a large number of fully humanized antibodies.
By inoculating cattle with different pathogens, they can produce polyclonal antibodies that target specific pathogens
In this randomized, double-blind, placebo-controlled Phase 2a clinical trial, healthy volunteers received SAB-176 or placebo and were nasally inoculated with H1N1 influenza virus.
Eight days after the inoculation, the nasopharyngeal swab samples The analysis of the viral load in SAB-176 found that compared with placebo, patients treated with SAB-176 had a significantly lower H1N1 viral load (one-sided p=0.
In addition, in patients with symptoms, SAB-176 significantly reduced the clinical symptoms of influenza compared with placebo (one-sided p=0.
In this study, SAB-176 showed good safety and tolerability, no serious adverse events related to it were observed, and most of the adverse events were mild or moderate
 SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus.
Retrieved December 1, 2021, from https://ir.
(The original text has been deleted)